LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...
The Food and Drug Administration Wednesday approved Irvine-based Edwards Lifesciences Corp.’s Sapien 3 less-invasive heart valve. Sapien 3 is approved for patients with narrowing aortic heart valves ...
Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Review staff from the US Food and Drug Administration (FDA) said Edwards Lifesciences' Sapien Transcatheter Heart Valve (THV) met trial endpoints for safety and effectiveness for the treatment of high ...
A Food and Drug Administration advisory panel on Wednesday cleared a replacement heart valve made by Irvine-based Edwards Lifesciences Corp. for patients too sick to have open-heart surgery. Edwards ...
About 300,000 patients nationally suffer from degradation of the aortic heart valve, which forces the heart to work harder to pump blood, often leading to heart failure, blood clots and sudden death.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results